European Biotech Act 1

As a cornerstone of the EU’s Life Sciences Strategy, the law will make Europe the most attractive place for biotech by 2030 by speeding approvals and risk assessments without compromising safety, unlocking risk-tolerant finance and biomanufacturing scale, building EU-wide clusters/infrastructure, closing skills gaps, and enabling trusted AI/data use (incl. supercomputing and EHDS links). It tackles single-market fragmentation across health, agri-food, industrial and marine biotech, strengthening competitiveness and economic security. Expected impacts of the law includes faster time-to-market, deeper investment pipelines, resilient supply chains and environmental benefits, supported by strong EU governance.